vs
Side-by-side financial comparison of RIGEL PHARMACEUTICALS INC (RIGL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $69.8M, roughly 1.0× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -49.0%, a 433.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 21.2%).
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
RIGL vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $69.8M | $70.6M |
| Net Profit | $268.1M | $-34.6M |
| Gross Margin | 91.5% | — |
| Operating Margin | 33.2% | -56.7% |
| Net Margin | 384.0% | -49.0% |
| Revenue YoY | 21.2% | 81958.1% |
| Net Profit YoY | 1769.2% | 54.9% |
| EPS (diluted) | $14.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $69.8M | — | ||
| Q3 25 | $69.5M | $70.6M | ||
| Q2 25 | $101.7M | — | ||
| Q1 25 | $53.3M | — | ||
| Q4 24 | $57.6M | — | ||
| Q3 24 | $55.3M | — | ||
| Q2 24 | $36.8M | — | ||
| Q1 24 | $29.5M | — |
| Q4 25 | $268.1M | — | ||
| Q3 25 | $27.9M | $-34.6M | ||
| Q2 25 | $59.6M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-8.2M | — |
| Q4 25 | 91.5% | — | ||
| Q3 25 | 93.2% | — | ||
| Q2 25 | 95.6% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 89.9% | — | ||
| Q3 24 | 85.5% | — | ||
| Q2 24 | 92.4% | — | ||
| Q1 24 | 93.1% | — |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 40.9% | -56.7% | ||
| Q2 25 | 60.1% | — | ||
| Q1 25 | 23.9% | — | ||
| Q4 24 | 28.9% | — | ||
| Q3 24 | 25.4% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | -23.6% | — |
| Q4 25 | 384.0% | — | ||
| Q3 25 | 40.2% | -49.0% | ||
| Q2 25 | 58.6% | — | ||
| Q1 25 | 21.5% | — | ||
| Q4 24 | 24.9% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | -2.8% | — | ||
| Q1 24 | -27.9% | — |
| Q4 25 | $14.11 | — | ||
| Q3 25 | $1.46 | — | ||
| Q2 25 | $3.28 | — | ||
| Q1 25 | $0.63 | — | ||
| Q4 24 | $0.82 | — | ||
| Q3 24 | $0.70 | — | ||
| Q2 24 | $-0.06 | — | ||
| Q1 24 | $-0.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $155.0M | $490.9M |
| Total DebtLower is stronger | $52.5M | — |
| Stockholders' EquityBook value | $391.5M | $503.0M |
| Total Assets | $513.6M | $577.1M |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $155.0M | — | ||
| Q3 25 | $137.1M | $490.9M | ||
| Q2 25 | $108.4M | — | ||
| Q1 25 | $77.1M | — | ||
| Q4 24 | $77.3M | — | ||
| Q3 24 | $61.1M | — | ||
| Q2 24 | $49.1M | — | ||
| Q1 24 | $49.5M | — |
| Q4 25 | $52.5M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $60.0M | — | ||
| Q1 25 | $60.0M | — | ||
| Q4 24 | $60.0M | — | ||
| Q3 24 | $60.0M | — | ||
| Q2 24 | $60.0M | — | ||
| Q1 24 | $60.0M | — |
| Q4 25 | $391.5M | — | ||
| Q3 25 | $117.6M | $503.0M | ||
| Q2 25 | $81.9M | — | ||
| Q1 25 | $18.6M | — | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $-14.6M | — | ||
| Q2 24 | $-29.9M | — | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | $513.6M | — | ||
| Q3 25 | $242.5M | $577.1M | ||
| Q2 25 | $206.7M | — | ||
| Q1 25 | $176.0M | — | ||
| Q4 24 | $164.0M | — | ||
| Q3 24 | $139.4M | — | ||
| Q2 24 | $128.4M | — | ||
| Q1 24 | $126.5M | — |
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 3.23× | — | ||
| Q4 24 | 18.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.0M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 0.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.0M | — | ||
| Q3 25 | $24.0M | $-84.6M | ||
| Q2 25 | $30.5M | — | ||
| Q1 25 | $-893.0K | — | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | $21.7M | — | ||
| Q2 24 | $302.0K | — | ||
| Q1 24 | $-5.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | 1.01× | — | ||
| Q3 24 | 1.75× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
